The medical cost of each case was chosen as the target variable of the 3933 patients, the mean inpatient medical expenditure with unstable angina
pectoris was RMB 41,078.
The above table depicts that mean serum ferritin levels in Acute Myocardial Infarction, Unstable Angina
and Controls were 81.
This study enrolled 2220 men and women with unstable angina
or non-ST segment elevation myocardial infarction.
We evaluated the associations of various clinical, laboratory, and angiographic predictors with an unstable angina
presentation using univariate and multivariate logistic regressions with maximization of likelihood.
In the UK, there are an estimated 120,000 hospital admissions for unstable angina
An important element of the guideline is its recommendation for the initial triage of patients with unstable angina
based on risk factors for poor short-term outcome: (1) high-risk patients: admit to an intensive care bed, (2) intermediate-risk patients: admit to a telemetry or intensive care bed, (3) low-risk patients: outpatient management with close follow-up (Braunwald et al.
Frei suggests that a patient with unstable angina
pectoris or coronary heart disease might be prudent to take up to a 500-mg supplement of vitamin C daily.
White said the drug will save the lives of 13 of every 1,000 unstable angina
It is also for people with a family member or friend who has unstable angina
or stable angina.
1 List of Tables and Figures 2 Unstable Angina
Therapeutics - Introduction 3 Unstable Angina
Therapeutics - Market Characterization 4 Unstable Angina
Therapeutics - Competitive Assessment 5 Unstable Angina
Therapeutics - Pipeline Assessment 6 Unstable Angina
Therapeutics - Clinical Trials Mapping 7 Unstable Angina
Therapeutics - Strategic Assessment 8 Unstable Angina
Therapeutics - Future Players 9 Unstable Angina
Therapeutics - Licensing & Partnership Deals 10 Unstable Angina
Therapeutics - Appendix
Prediction of outcome of any clinical episode of unstable angina
has been extremely difficult.
Biopharmaceutical company AstraZeneca (NYSE:AZN) announced on Monday that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for the use of the oral antiplatelet medicine, BRILINTA (ticagrelor) tablets in patients with Unstable Angina
(UA) or Non-ST-Elevation Myocardial Infarction (NSTEMI) managed both invasively and non-invasively.